cbdMD (YCBD) Change in Account Payables (2019)
cbdMD (YCBD) posted Change in Account Payables of $306089.0 for Q3 2019, up 285.38% sequentially from $79425.0 in Q2 2019.
cbdMD (YCBD) Change in Account Payables (2019) Analysis & Trends
cbdMD has reported Change in Account Payables for 1 years, with the latest figure at $306089.0 in Q3 2019.
- Quarterly Change in Account Payables changed N/A year-over-year to $306089.0 in Q3 2019, while the trailing twelve-month figure through Sep 2020 was $385514.0 (changed N/A YoY) and the FY2019 annual result came in at -$7502.0, changed N/A from the prior year.
- Change in Account Payables improved to $306089.0 in Q3 2019 per YCBD's latest filing, from $79425.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $306089.0 in Q3 2019 and troughed at $79425.0 in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 306,089.00 |
| Sep 30, 2019 | 306,089.00 |
| Jun 30, 2019 | 79,425.00 |
| Jun 30, 2019 | 79,425.00 |